<DOC>
	<DOCNO>NCT01311960</DOCNO>
	<brief_summary>The purpose study determine whether bevacizumab eye drop effective treatment recurrent pterygium .</brief_summary>
	<brief_title>Topical Bevacizumab Preventing Recurrent Pterygium</brief_title>
	<detailed_description>A pterygium degenerative proliferative fibrovascular disorder ocular surface . Patients may asymptomatic , irritation , decrease vision , diplopia limit ocular movement . The mainstay treatment surgical removal head , neck body pterygium . However , adjunctive treatment , recurrence unacceptably high 63 % general . Various adjunctive measure apply prevent recurrence include use mitomycin C , beta-irradiation surgical method conjunctival amniotic membrane graft . However , method advantage disadvantage . The histologic finding recurrent pterygium often aggressive fibrovascular growth . Vascular endothelial growth factor ( VEGF ) detect increased amount pterygium tissue , compare normal conjunctiva also correlate post-operative recurrence . Bevacizumab , Anti-VEGF , bind VEGF prevents interaction VEGF receptor surface vascular endothelial cell . Administration bevacizumab lead inhibition endothelial cell proliferation new blood vessel formation . Even though report efficacy topical bevacizumab inhibit impend recurrent pterygium , study prevent recurrence primary pterygium removal . We conduct prospective , randomize , double-masked , controlled trial evaluate efficacy topical bevacizumab 0.05 % eye drop prevent recurrence primary pterygium .</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patients diagnose primary pterygium plan pterygium excision bare sclera single surgeon . ( G.N . ) Patients pterygium understand follow study protocol . Patients age 30 year Patients corneal melt , corneal epitheliopathy , abnormal corneal epithelial wound healing . Patients pregnancy lactation . Patients history allergy bevacizumab . Patients history allergy steroid eye drop</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>pterygium</keyword>
	<keyword>recurrent pterygium</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>VEGF</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>